Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24808574 | 0.83 | ALDH1A1 (0.38) | ALDH1A1LMNAKDM4EPOLBMAPT | |
| SCHEMBL4015672 | 0.76 | ELANE (0.40) | ALDH1A1LMNAKDM4EPOLBMAPT | |
| SCHEMBL1401945 | 0.73 | RXRA (0.43) | IDO1DHODH | |
| SCHEMBL1401938 | 0.73 | RXRA (0.44) | IDO1DHODH | |
| SCHEMBL1401939 | 0.69 | RXRA (0.46) | IDO1DHODH | |
| SCHEMBL1401932 | 0.66 | RXRA (0.50) | ALDH1A1KDM4EIDO1HPGDSMN1; SMN2 | |
| SCHEMBL16147917 | 0.65 | ELANE (0.47) | ALDH1A1KDM4EPOLBMAPTHPGD | |
| SCHEMBL6226096 | 0.65 | ELANE (0.38) | ALDH1A1LMNAKDM4EPOLBMAPT | |
| SCHEMBL14321663 | 0.65 | CYP4F2 (0.37) | — | |
| SCHEMBL30049306 | 0.64 | ELANE (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106697-A1 | METHODS FOR MAKING RETINOIDS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2016-04-21 | — | — | US | disclosed |
| US-9169190-B2 | Methods for making retinoids and uses thereof | THE UAB RESEARCH FOUNDATION (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2292576-B1 | Retinoids useful in the treatment of cancer and for reducing serum triglycerides | UAB RESEARCH FOUNDATION (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130317106-A1 | METHODS FOR MAKING RETINOIDS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2292576-A2 | Retinoids useful in the treatment of cancer and for reducing serum triglycerides | The UAB Research Foundation (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100204327-A1 | Methods for making retinoids and uses thereof | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2010-08-12 | — | — | US | disclosed |
| EP-1791426-A2 | METHODS FOR MAKING RETINOIDS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006036394-A2 | METHODS FOR MAKING RETINOIDS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317106-A1 | METHODS FOR MAKING RETINOIDS AND USES THEREOF | RARB, RARA, RARG | ALDH1A1 63/4885LMNA 882/4885KDM4E 3265/4885 |
| US-20100204327-A1 | Methods for making retinoids and uses thereof | RARB, RARA, RARG | ALDH1A1 63/4885LMNA 882/4885KDM4E 3265/4885 |
| US-20160106697-A1 | METHODS FOR MAKING RETINOIDS AND USES THEREOF | RARB, RARA, RARG | ALDH1A1 63/4885LMNA 882/4885KDM4E 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.